<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-024-52894-2
   </article-id>
   <article-id pub-id-type="manuscript">
    52894
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-024-52894-2
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/53/2423
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/308/174
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699/67
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /82/58
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Uchunguzi wa Plasma Proteomic na Polygenic unaoboresha utambuzi wa hatari na utambuzi wa kibinafsi wa saratani ya utumbo
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" equal-contrib="yes" id="Au1">
     <name name-style="western">
      <surname>
       Sun
      </surname>
      <given-names>
       Jing
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" equal-contrib="yes" id="Au2">
     <name name-style="western">
      <surname>
       Liu
      </surname>
      <given-names>
       Yue
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Zhao
      </surname>
      <given-names>
       Jianhui
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Lu
      </surname>
      <given-names>
       Bin
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Zhou
      </surname>
      <given-names>
       Siyun
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Lu
      </surname>
      <given-names>
       Wei
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <name name-style="western">
      <surname>
       Wei
      </surname>
      <given-names>
       Jingsun
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <name name-style="western">
      <surname>
       Hu
      </surname>
      <given-names>
       Yeting
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <name name-style="western">
      <surname>
       Kong
      </surname>
      <given-names>
       Xiangxing
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <name name-style="western">
      <surname>
       Gao
      </surname>
      <given-names>
       Junshun
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au11">
     <name name-style="western">
      <surname>
       Guan
      </surname>
      <given-names>
       Hong
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au12">
     <name name-style="western">
      <surname>
       Gao
      </surname>
      <given-names>
       Junli
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="author-notes" rid="fn2"/>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au13">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-0120-2371
     </contrib-id>
     <name name-style="western">
      <surname>
       Xiao
      </surname>
      <given-names>
       Qian
      </given-names>
     </name>
     <address>
      <email>
       qxiao3@zju.edu.cn
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="corresp" rid="IDs41467024528942_cor13">
      p
     </xref>
     <xref ref-type="author-notes" rid="fn2"/>
    </contrib>
    <contrib contrib-type="author" id="Au14">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-6880-2577
     </contrib-id>
     <name name-style="western">
      <surname>
       Li
      </surname>
      <given-names>
       Xue
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="author-notes" rid="fn2"/>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/059cjpv64
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.412465.0
      </institution-id>
      <institution content-type="org-division">
       Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education)
      </institution>
      <institution content-type="org-name">
       The Second Affiliated Hospital, Zhejiang University School of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.13402.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1759 700X
      </institution-id>
      <institution content-type="org-division">
       Department of Big Data in Health Science, School of Public Health and The Second Affiliated Hospital
      </institution>
      <institution content-type="org-name">
       Zhejiang University School of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.419897.a
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0369 313X
      </institution-id>
      <institution content-type="org-name">
       Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       Zhejiang Provincial Clinical Research Center for CANCER
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00a2xv884
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.13402.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1759 700X
      </institution-id>
      <institution content-type="org-name">
       Cancer Center of Zhejiang University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/059cjpv64
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.412465.0
      </institution-id>
      <institution content-type="org-division">
       Nursing Department
      </institution>
      <institution content-type="org-name">
       The Second Affiliated Hospital of Zhejiang University School of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00a2xv884
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.13402.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1759 700X
      </institution-id>
      <institution content-type="org-name">
       Cosmos Wisdom Mass Spectrometry Center of Zhejiang University Medical School
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <fn fn-type="equal" id="fn1">
     <p>
      These authors contributed equally: Jing Sun, Yue Liu.
     </p>
    </fn>
    <fn fn-type="con" id="fn2">
     <p>
      These authors are jointly supervised this work: Junli Gao, Qian Xiao, Xue Li.
     </p>
    </fn>
    <corresp id="IDs41467024528942_cor13">
     <label>
      p
     </label>
     <email>
      qxiao3@zju.edu.cn
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     15
    </day>
    <month>
     10
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="8873">
    1
   </issue>
   <elocation-id>
    8873
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      25
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="received">
     <day>
      21
     </day>
     <month>
      2
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="accepted">
     <day>
      20
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="online">
     <day>
      15
     </day>
     <month>
      10
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
       http://creativecommons.org/licenses/by-nc-nd/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Maelezo
    </title>
    <p id="Par1">
     Utafiti huu unalenga kutambua viambajengo vya saratani ya utumbo (CRC) na kubuni muundo wa utabiri wa kuanza kwa CRC kwa kuchanganya viambajengo vya proteomic na mambo ya kijeni na yasiyo ya kijeni (QCancer-15) ili kuboresha utambuzi wa hatari na kuhesabu umri wa awali wa utambuzi wa kibinafsi. Hapa, kwa kutumia mkakati wa hatua mbili, tunatanguliza viambajengo 15 vya protini kama vibashiri kuunda alama ya hatari ya protini (ProS). Muundo wa utabiri wa hatari unaochanganya viambajengo vya proteomic na alama ya hatari ya polygenic (PRS) na alama ya hatari ya QCancer-15 (QCancer-S) unaonyesha utendakazi ulioboreshwa (C-statistic: 0.79 vs. 0.71,
     <italic>
      P
     </italic>
     = 4.94E–03 katika kundi la mafunzo; 0.75 vs 0.69,
     <italic>
      P
     </italic>
     = 5.49E–04 katika kundi la uthibitisho) na manufaa ya neti kuliko QCancer-S pekee. Muundo wa pamoja unatambua kwa uwazi hatari ya kuanza kwa CRC. Washiriki walio na ProS ya juu, PRS, au alama ya hatari ya pamoja wanapendekezwa kuanza utambuzi wa umri wa miaka 46, 41, au kabla ya miaka 40. Katika kazi hii, ujumuishaji wa uchunguzi wa damu wa proteomic na PRS na QCancer-15 unaonyesha utendakazi ulioboreshwa wa utambuzi wa hatari na athari za kimatibabu kwa uchimbaji wa umri wa awali wa utambuzi wa CRC, ambao unaweza kuchangia katika mchakato wa kufanya maamuzi kwa utambuzi wa CRC.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     Non-invasive approaches for risk stratification and screening remain crucial for colorectal cancer (CRC). Here, the authors develop a model for CRC risk stratification by integrating plasma proteomics data with polygenic risk score and QCancer-15 risk score, which could guide recommendations for earlier screening of high-risk populations.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1117">
      Public Health and Health Services
     </kwd>
    </nested-kwd>
   </kwd-group>
   <funding-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        National Natural Science Foundation of China (National Science Foundation of China)
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        https://doi.org/10.13039/501100001809
       </institution-id>
      </institution-wrap>
     </funding-source>
     <award-id award-type="FundRef grant">
      82072360
     </award-id>
     <award-id award-type="FundRef grant">
      82373234
     </award-id>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Xiao
       </surname>
       <given-names>
        Qian
       </given-names>
      </name>
     </principal-award-recipient>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Xiao
       </surname>
       <given-names>
        Qian
       </given-names>
      </name>
     </principal-award-recipient>
    </award-group>
   </funding-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      8873
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      9
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      25
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2024_Article_52894.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Utangulizi
   </title>
   <p id="Par3">
    Saratan ya utumbo wa miguu (CRC) ni ya tatu kwa ugonjwa wa saratani na sababu ya pili ya kifo cha saratani duniani kote
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Hivi sasa, njia bora zaidi ya kupunguza mizigo ya CRC ni utambuzi wa mapema kwa uchunguzi wa idadi ya watu. Ingawa njia za uchunguzi zinatofautiana kimataifa, programu za uchunguzi zimejikita zaidi kwenye umri na historia ya familia na hazizingatii mambo mengine ya hatari. Hata hivyo, ushahidi unaojumlisha unaonyesha kwamba tofauti kubwa ya hatari ya CRC kati ya watu si tu inayohusishwa na umri na historia ya familia, hasa kiwango cha kuibuka kwa mapema kwa CRC kimeongezeka kwa miaka michache iliyopita
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Zaidi ya hayo, kwa kuzingatia kwamba kolonoskopia (kiwango cha juu) ni ya uvamizi, inachukua muda, na ghali, utambuzi zaidi wa uchunguzi wa mapema na violezo vya utambuzi na maendeleo ya mapendekezo ya uchunguzi yaliyotegemea hatari na ya kibinafsi kwa ajili ya kuboresha ufanisi wa uchunguzi unahitajika sana.
   </p>
   <p id="Par4">
    Vitamuni vya damu, vinavyoonekana katika mzunguko wa damu kwa sababu ya utoaji wa shughuli au kutolewa kwa seli, hutolewa kwa uwakilishi wa hali za afya za binadamu na magonjwa na hutenda kama hifadhi kubwa ya violezo na malengo ya matibabu, yakishikilia upatikanaji rahisi zaidi na uwezo wa kutabiri magonjwa
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
    </sup>
    . Baadhi ya masomo yametokana na uhusiano mkali kati ya protini zinazosogea na hatari ya CRC na yamependekeza kuwa violezo vya protini vina uwezo wa kutofautisha kesi za CRC na za udhibiti
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
     ,
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Hata hivyo, masomo haya ya utabiri yaliyoegemea protini yalikuwa yamejikita kwenye muundo wa kesi-udhibiti, na ukubwa mdogo wa sampuli. Mafunzo ya muda mrefu kwa idadi ya watu, kwa nadharia, ni ya kuaminika zaidi kwa ajili ya kuhesabu saini za molekuli za mapema zinazohusiana na kuanza kwa ugonjwa kwa ajili ya utambuzi wa hatari. Zaidi ya hayo, sababu za kijeni na zisizo za kijeni zilizothibitishwa (kwa mfano, QCancer-[15 yr, colorectal]) pia huchukua jukumu muhimu katika kutokea kwa CRC na kuchangia katika utambuzi wa hatari wa CRC
    <sup>
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
     ,
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
    </sup>
    . Kukamata protini zinazosogea, pamoja na sababu za kijeni na zisizo za kijeni kwa wakati mmoja kunaweza kutarajiwa kuendeleza zana za utabiri zenye matumizi bora ya kimatibabu katika CRC.
   </p>
   <p id="Par5">
    Katika kazi hii, tunatumia mkakati wa hatua mbili kulingana na kesi-udhibiti na kikundi cha idadi ya watu kwa ajili ya kubainisha na kuthibitisha saini za proteomiki zinazohusiana na CRC (Fig.
    <xref ref-type="fig" rid="Fig1">
     1
    </xref>
    ). Kisha, alama za hatari za QCancer-15 na alama za hatari za polygenic (PRSs) zimeundwa na kuchanganywa na violezo muhimu vya protini kwa ajili ya kuendeleza muundo wa utabiri wa kuanza kwa CRC. Mwisho, tunathibitisha utendakazi wa utabiri wa muundo uliojumuishwa na manufaa yanayowezekana ya kimatibabu katika kipengele cha manufaa ya wazi, utambuzi wa hatari, na umri wa kibinafsi wa kuanza kwa uchunguzi wa CRC.
    <fig/>
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <sec id="Sec3">
    <title>
     Viashiria vya Proteomic vya CRC
    </title>
    <p id="Par6">
     Katika hatua ya ugunduzi, jumla ya protini 421 zilizoonyeshwa tofauti za plasma zilipaywa kati ya kesi za CRC na za udhibiti, na protini 243 zilizoongezeka (Log2 mabadiliko ya kugeuza, Log
     <sub>
      2
     </sub>
     FC &gt; 0, kiwango cha kupunguza uvumbuzi, FDR
     <table-wrap id="Tab1">
      <label>
       Table 1
      </label>
      <caption xml:lang="en">
       <p>
        Sifa za msingi za washiriki
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th>
          <p>
           Sifa
          </p>
         </th>
         <th>
          <p>
           Washiriki wote
          </p>
         </th>
         <th>
          <p>
           Matukio ya CRC
          </p>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td>
          <p>
           Idadi ya washiriki
          </p>
         </td>
         <td>
          <p>
           52,231
          </p>
         </td>
         <td>
          <p>
           731
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Ufuatiliaji (miaka), wastani (IQR)
          </p>
         </td>
         <td>
          <p>
           13.05 (12.38, 13.75)
          </p>
         </td>
         <td>
          <p>
           6.69 (3.49, 9.34)
          </p>
         </td>
        </tr>
        <tr>
         <td colspan="3">
          <p>
           Jinsia
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mwanamke
          </p>
         </td>
         <td>
          <p>
           28,196 (54%)
          </p>
         </td>
         <td>
          <p>
           305 (42%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mwanaume
          </p>
         </td>
         <td>
          <p>
           24,035 (46%)
          </p>
         </td>
         <td>
          <p>
           426 (58%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Umri (miaka), wastani (IQR)
          </p>
         </td>
         <td>
          <p>
           58 (50, 64)
          </p>
         </td>
         <td>
          <p>
           62 (57, 66)
          </p>
         </td>
        </tr>
        <tr>
         <td colspan="3">
          <p>
           Ubangiliaji
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Weupe/siwe na rekodi
          </p>
         </td>
         <td>
          <p>
           48,951 (94%)
          </p>
         </td>
         <td>
          <p>
           702 (96%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mwafrika mweusi
          </p>
         </td>
         <td>
          <p>
           684 (1.3%)
          </p>
         </td>
         <td>
          <p>
           8 (1.1%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Kariibi
          </p>
         </td>
         <td>
          <p>
           502 (1.0%)
          </p>
         </td>
         <td>
          <p>
           3 (0.4%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mhindi
          </p>
         </td>
         <td>
          <p>
           581 (1.1%)
          </p>
         </td>
         <td>
          <p>
           2 (0.3%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Pakistani
          </p>
         </td>
         <td>
          <p>
           172 (0.3%)
          </p>
         </td>
         <td>
          <p>
           3 (0.4%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Bangladeshi
          </p>
         </td>
         <td>
          <p>
           29 (&lt;0.1%)
          </p>
         </td>
         <td>
          <p>
           0 (0%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mwasiati mwingine
          </p>
         </td>
         <td>
          <p>
           192 (0.4%)
          </p>
         </td>
         <td>
          <p>
           3 (0.4%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mchina
          </p>
         </td>
         <td>
          <p>
           147 (0.3%)
          </p>
         </td>
         <td>
          <p>
           4 (0.5%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mwingine
          </p>
         </td>
         <td>
          <p>
           973 (1.9%)
          </p>
         </td>
         <td>
          <p>
           6 (0.8%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Viwango vya Townsend vya kuchanganyikiwa, wastani (IQR)
          </p>
         </td>
         <td>
          <p>
           –2.1 (–3.6, 0.8)
          </p>
         </td>
         <td>
          <p>
           –2.1 (–3.5, 0.6)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Viwango vya msingi vya kimetaboliki (BMI), wastani (IQR)
          </p>
         </td>
         <td>
          <p>
           26.8 (24.2, 29.9)
          </p>
         </td>
         <td>
          <p>
           27.3 (24.8, 29.9)
          </p>
         </td>
        </tr>
        <tr>
         <td colspan="3">
          <p>
           Kuvuta sigara
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Sio mvutaji sigara
          </p>
         </td>
         <td>
          <p>
           28,304 (54%)
          </p>
         </td>
         <td>
          <p>
           344 (47%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Aliacha kuvuta sigara
          </p>
         </td>
         <td>
          <p>
           18,160 (35%)
          </p>
         </td>
         <td>
          <p>
           319 (44%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mvutaji sigara mdogo
          </p>
         </td>
         <td>
          <p>
           2258 (4.3%)
          </p>
         </td>
         <td>
          <p>
           23 (3.1%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mvutaji sigara wa wastani
          </p>
         </td>
         <td>
          <p>
           1617 (3.1%)
          </p>
         </td>
         <td>
          <p>
           16 (2.2%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mvutaji sigara mkubwa
          </p>
         </td>
         <td>
          <p>
           1379 (2.6%)
          </p>
         </td>
         <td>
          <p>
           20 (2.7%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Hakuna taarifa
          </p>
         </td>
         <td>
          <p>
           513 (1.0%)
          </p>
         </td>
         <td>
          <p>
           9 (1.2%)
          </p>
         </td>
        </tr>
        <tr>
         <td colspan="3">
          <p>
           Uzito wa pombe
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Sio mpiga pombe
          </p>
         </td>
         <td>
          <p>
           4504 (8.6%)
          </p>
         </td>
         <td>
          <p>
           61 (8.3%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mpiga pombe kidogo
          </p>
         </td>
         <td>
          <p>
           6189 (12%)
          </p>
         </td>
         <td>
          <p>
           79 (11%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mpiga pombe mdogo
          </p>
         </td>
         <td>
          <p>
           15,584 (30%)
          </p>
         </td>
         <td>
          <p>
           203 (28%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mpiga pombe wa wastani
          </p>
         </td>
         <td>
          <p>
           10,514 (20%)
          </p>
         </td>
         <td>
          <p>
           168 (23%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mpiga pombe mkubwa
          </p>
         </td>
         <td>
          <p>
           1946 (3.7%)
          </p>
         </td>
         <td>
          <p>
           37 (5.1%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mpiga pombe mwingi
          </p>
         </td>
         <td>
          <p>
           1285 (2.5%)
          </p>
         </td>
         <td>
          <p>
           35 (4.8%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Hakuna taarifa
          </p>
         </td>
         <td>
          <p>
           12,209 (23%)
          </p>
         </td>
         <td>
          <p>
           148 (20%)
          </p>
         </td>
        </tr>
        <tr>
         <td colspan="3">
          <p>
           Historia ya familia ya saratani ya coloni
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Hapana
          </p>
         </td>
         <td>
          <p>
           47,614 (91%)
          </p>
         </td>
         <td>
          <p>
           633 (87%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Ndiyo
          </p>
         </td>
         <td>
          <p>
           3569 (6.8%)
          </p>
         </td>
         <td>
          <p>
           81 (11%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Hakuna taarifa
          </p>
         </td>
         <td>
          <p>
           1048 (2.0%)
          </p>
         </td>
         <td>
          <p>
           17 (2.3%)
          </p>
         </td>
        </tr>
        <tr>
         <td colspan="3">
          <p>
           Historia ya matibabu
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Kisukari
          </p>
         </td>
         <td>
          <p>
           742 (1.4%)
          </p>
         </td>
         <td>
          <p>
           13 (1.8%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Kolitis ya ulcers
          </p>
         </td>
         <td>
          <p>
           114 (0.2%)
          </p>
         </td>
         <td>
          <p>
           3 (0.4%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Polipi za bowel
          </p>
         </td>
         <td>
          <p>
           26 (&lt;0.1%)
          </p>
         </td>
         <td>
          <p>
           0 (0%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Saratani ya konzi
          </p>
         </td>
         <td>
          <p>
           1105 (2.1%)
          </p>
         </td>
         <td>
          <p>
           17 (2.3%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Saratani ya utero
          </p>
         </td>
         <td>
          <p>
           113 (0.2%)
          </p>
         </td>
         <td>
          <p>
           2 (0.3%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Saratani ya ovari
          </p>
         </td>
         <td>
          <p>
           80 (0.2%)
          </p>
         </td>
         <td>
          <p>
           1 (0.1%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Saratani ya shingo
          </p>
         </td>
         <td>
          <p>
           220 (0.4%)
          </p>
         </td>
         <td>
          <p>
           0 (0%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Saratani ya mapafu
          </p>
         </td>
         <td>
          <p>
           46 (&lt;0.1%)
          </p>
         </td>
         <td>
          <p>
           1 (0.1%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Saratani ya damu
          </p>
         </td>
         <td>
          <p>
           263 (0.5%)
          </p>
         </td>
         <td>
          <p>
           6 (0.8%)
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Saratani ya mdomo
          </p>
         </td>
         <td>
          <p>
           99 (0.2%)
          </p>
         </td>
         <td>
          <p>
           3 (0.4%)
          </p>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        <italic>
         CRC
        </italic>
        saratani ya coloni,
        <italic>
         IQR
        </italic>
        interquartile range.
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     Ujenzi wa Alama za Hatari
    </title>
    <p id="Par7">
     Kati ya protini 88 zilizobainishwa na mkakati wa hatua mbili, mchakato wa LASSO-Cox ulitumika kwa ajili ya kuchagua saini za protini zinazohusiana na hatari ya CRC. Kwa hiyo, violezo 15 vya protini biomarkers (IGFBP4, WFDC2, TFF1, LTBP2, COL18A1, CCN3, SELL, PON3, ADGRG2, IGF2R, PZP, CDON, TNXB, APLP1, CR2) zilichaguliwa mwisho kwa ajili ya kuunda alama ya hatari ya protini (ProS) kwa hatari ya CRC (Fig.
     <xref ref-type="fig" rid="Fig2">
      2
     </xref>
     , Fig ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ). Sifa za msingi zilizojumuishwa katika vichambuzi vya QCancer-15 vya UKBB zinaonyeshwa katika Jedwali
     <xref ref-type="table" rid="Tab1">
      1
     </xref>
     <sup/>
     . Alama ya ProS iliyoundwa (HR: 1.24 kwa ongezeko la SD, 95% kiwango cha uaminifu [CI]: 1.21–1.28,
     <italic>
      P
     </italic>
     = 1.85 × 10) na alama ya hatari ya QCancer-15 (QCancer-S) (HR: 1.55 kwa ongezeko la SD, 95% CI: 1.48–1.62,
     <italic>
      P
     </italic>
     = 1.51 × 10) zilikuwa chanya zinazohusiana na CRC iliyogunduliwa (Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ). Kwa kutumia LDpred2, jumla ya PRS 2 ziliundwa. Zote mbili za PRS zilikuwa chanya zinazohusiana na CRC iliyogunduliwa, na HR kwa kila SD ya PRS kwa hatari ya CRC ilikuwa 1.46 kwa LDpred2-auto na 2.31 kwa LDpred2-grid (95% CI: 2.15–2.48,
     <italic>
      P
     </italic>
     = 4.36 × 10) (Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     )
     <sup/>
     .
     <fig/>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     Maendeleo na Tathmini ya Muundo wa Kubashiri
    </title>
    <p id="Par8">
     Mfano wa kutabiri uliotokana na QCancer-S, PRSs, na ProS ulijengwa katika UKBB, kwa mtiririko huo. Katika kundi la mafunzo, takwimu za C kwa QCancer-S na QCancer-S (ikiwa ni pamoja na eneo la kijiografia) zilikuwa 0.71 (95% CI: 0.66, 0.76), na hakukuwa na tofauti ya kimahesabu (
     <italic>
      P
     </italic>
     = 0.63) (Fig.
     <xref ref-type="fig" rid="Fig3">
      3a
     </xref>
     , Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ). Kwa ajili ya ujumuishaji, QCancer-S iliyotumika katika uundaji na uchambuzi wa baadaye. Takwimu za C kwa ProS zilikuwa 0.66 (95% CI: 0.61, 0.71) (Fig.
     <xref ref-type="fig" rid="Fig3">
      3a
     </xref>
     ). Kati ya miundo 2 ya PRS, LDpred2-grid ilifanya vizuri zaidi, na takwimu ya C ya 0.74 (95% CI: 0.69, 0.80) (Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ). Kisha PRS (LDpred2-grid) yenye utendakazi bora zaidi ilichanganywa na QCancer-S na ProS kuunda mfano wa pamoja, na takwimu ya C ilifikia 0.79 (95% CI: 0.75, 0.84), ambayo iliboreshwa zaidi kuliko muundo wa QCancer-S pekee katika makundi ya mafunzo (takwimu ya C: 0.79 vs. 0.71,
     <italic>
      P
     </italic>
     = 4.94E–03) na uthibitishaji (takwimu ya C: 0.75 vs 0.69,
     <italic>
      P
     </italic>
     = 5.49E–04) (Fig.
     <xref ref-type="fig" rid="Fig3">
      3a
     </xref>
     , Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ).
     <fig/>
    </p>
    <p id="Par9">
     Matokeo ya uchambuzi uliogawanyika yameonyeshwa katika Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      3
     </xref>
     <sup/>
     . Katika kundi la mafunzo, takwimu ya C ya muundo uliopangwa ulikuwa 0.76 (95% CI: 0.69, 0.83) kwa wanawake na 0.77 (95% CI: 0.70, 0.84) kwa wanaume. Wakati wa kuzingatia hatari ya CRC kwa kujitegemea kwa colon na rectum, takwimu ya C ya muundo uliopangwa ilifikia 0.79 (95% CI: 0.74, 0.85) kwa saratani ya colon na 0.82 (95% CI: 0.73, 0.91) kwa saratani ya rectum. Muundo uliopangwa ulitendeka vizuri zaidi kuliko QCancer-S pekee bila kujali kama washiriki walikuwa wamechunguzwa awali kwa saratani ya bowel au kama walikuwa na historia ya familia ya CRC. Takwimu ya C ya muundo uliopangwa ilifikia 0.79 (95% CI: 0.73, 0.85) kwa washiriki bila uchunguzi, 0.79 (95% CI: 0.62, 0.95) kwa washiriki ambao walikuwa wamechunguzwa awali kabla ya kujiandikisha kwenye UKBB mwaka mmoja na mapema, na 0.91 (95% CI: 0.85, 0.98) kwa washiriki wenye historia ya familia. Matokeo kama hayo yalionekana katika kundi la uthibitishaji. Kwa washiriki bila historia ya familia ya CRC na bila uchunguzi, muundo uliopangwa ulionyesha ubaguzi ulioboreshwa zaidi kuliko QCancer-S pekee katika makundi ya mafunzo (takwimu ya C, 0.82 vs. 0.71,
     <italic>
      P
     </italic>
     &lt; 0.05) na uthibitishaji (takwimu ya C, 0.75 vs. 0.71,
     <italic>
      P
     </italic>
     &lt; 0.05) vyote. Mivutano ya kalibreshaji ilionyesha kuwa viwango vilivyopimwa na vilivyoamuliwa vilikuwa na mshikamano mzuri (Fig.
     <xref ref-type="fig" rid="Fig3">
      3b
     </xref>
     , Fig. ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     ).
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     Manufaa ya Muundo wa Kubashiri
    </title>
    <p id="Par10">
     Machambuzi ya mkunjo wa maamuzi yalionyesha kuwa muundo uliopangwa ulikuwa na manufaa zaidi ya QCancer-S pekee katika safu mbalimbali za uwezekano wa hatari katika makundi ya mafunzo na uthibitishaji, pamoja na idadi ya jumla ya watu (Fig.
     <xref ref-type="fig" rid="Fig3">
      3c
     </xref>
     , Fig. ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     ). Kwa mfano, wakati uwezekano wa hatari ulikuwa 1%, manufaa ya mkunjo kwa muundo uliopangwa ilikuwa 0.65% katika idadi ya jumla ya watu (0.62% katika kundi la mafunzo, 0.71% katika kundi la uthibitishaji), maana kwamba ikilinganishwa na dhana kwamba hakuna mshiriki aliyeingiliwa, 65 (62 katika kundi la mafunzo, 71 katika kundi la uthibitishaji) CRC ziligunduliwa bila kuongezeka kwa uwezekano wa kupotosha na uchunguzi usiofaa wa colonoscopy kwa kila watu 10,000. Manufaa ya mkunjo kwa muundo uliopangwa ilikuwa 0.24% (0.24% katika kundi la mafunzo, 0.21% katika kundi la uthibitishaji) kubwa kuliko dhana kwamba washiriki wote walikuwa wameingiliwa na 0.10% (0.11% katika kundi la mafunzo, 0.06% katika kundi la uthibitishaji) kubwa kuliko muundo wa QCancer-S (Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      4
     </xref>
     ). Zaidi ya hayo, kulikuwa na 24 (24 katika kundi la mafunzo, 21 katika kundi la uthibitishaji) chini ya uwezekano wa kupotosha kwa muundo uliopangwa wakati 14 (13 katika kundi la mafunzo, 15 katika kundi la uthibitishaji) chini ya uwezekano wa kupotosha kwa muundo wa QCancer-S kwa kila watu 100. Katika mgawanyiko kwa ajili ya jinsia au tovuti ya tumor, muundo uliopangwa ulitendeka vizuri zaidi kuliko QCancer-S pekee (Fig. ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     ). Katika washiriki bila historia ya familia ya CRC na bila uchunguzi, thamani hizi zilikuwa 26 chini ya uwezekano wa kupotosha kwa miundo iliyopangwa wakati 16 chini ya uwezekano wa kupotosha kwa muundo wa QCancer-S kwa kila watu 100 (Fig. ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     , Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      4
     </xref>
     ).
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     Ugawanyaji wa Hatari wa CRC katika Makundi ya Hatari
    </title>
    <p id="Par11">
     Muundo uliopangwa kisha ulitumika kutathmini hatari ya CRC kwa washiriki, na nomogramu iliundwa kulingana na taarifa hizi katika idadi ya jumla ya watu, kundi la mafunzo, na kundi la uthibitishaji kama inavyoonyeshwa katika Fig.
     <xref ref-type="fig" rid="Fig3">
      3d
     </xref>
     na Fig. ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      4
     </xref>
     <sup/>
     . Baada ya kugawanya sehemu za muundo uliopangwa (QCancer-S, PRS, na ProS) na alama ya hatari iliyojumuishwa (ComS) katika vikundi vitatu (wazuri, wastani, na wa juu), kwa mtiririko huo, ikilinganishwa na kundi la wastani, washiriki katika kundi la juu la QCancer-S walikuwa na hatari kubwa zaidi ya CRC (HR: 1.91, 95% CI: 1.60–2.29) katika idadi ya jumla ya watu (HR [95% CI]: 2.06 [1.65–2.56] katika kundi la mafunzo, 1.66 [1.23–2.25] katika kundi la uthibitishaji), 2.5 mara kubwa ya hatari ya CRC kwa kundi la juu la PRS (HR: 2.71, 95% CI: 2.24–3.27) katika idadi ya jumla ya watu (HR [95% CI]: 2.84 [2.26–3.59] katika kundi la mafunzo, 2.46 [1.78–3.40] katika kundi la uthibitishaji), 1.5 mara kubwa ya hatari ya CRC kwa kundi la juu la ProS (HR: 1.67, 95% CI: 1.40–1.99) katika idadi ya jumla ya watu (HR [95% CI]: 1.78 [1.43–2.22] katika kundi la mafunzo, 1.48 [1.09–1.99] katika kundi la uthibitishaji), na mara tatu kubwa ya hatari ya CRC kwa kundi la juu la ComS (HR: 3.27, 95% CI: 2.71–3.96) katika idadi ya jumla ya watu (HR [95% CI]: 2.94 [2.35–3.67] katika kundi la mafunzo, 4.27 [2.96–6.18] katika kundi la uthibitishaji) (Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      5
     </xref>
     ). Fig.
     <xref ref-type="fig" rid="Fig4">
      4a–d
     </xref>
     na Fig. ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      5
     </xref>
     yanaonyesha mikunjo ya ukuaji wa hatari ya CRC katika vikundi vitatu vya hatari kulingana na alama nne za hatari katika idadi ya jumla ya watu, kundi la mafunzo, na kundi la uthibitishaji, kwa mtiririko huo, ikionyesha mgawanyiko wa wazi kati ya vikundi tofauti vya hatari (Log-rank
     <italic>
      P
     </italic>
     &lt; 0.0001) na vikundi vya hatari kulingana na ComS vinavyoonyesha mgawanyiko bora. Katika washiriki bila historia ya familia ya CRC na bila uchunguzi, ComS pia ilifanya vizuri katika mgawanyiko wa hatari (Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      5
     </xref>
     , Fig. ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      6
     </xref>
     ).
     <fig/>
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     Kipindi cha Kuongezeka kwa Hatari ya CRC katika Makundi tofauti ya Ugawanyaji
    </title>
    <p id="Par12">
     Zaidi ya hayo, washiriki katika kundi la juu la PRS walifikia hatari sawa ya CRC ~17.9 miaka (kipindi cha maendeleo ya hatari, RAP: 17.87, 95% CI: 12.91, 22.83) mapema kuliko washiriki wenye PRS katika kundi la wastani katika idadi ya jumla ya watu, wakati washiriki katika kundi la chini la PRS walikuwa miaka 8.9 baadaye kuliko kundi la wastani (RAP: –8.93, 95% CI: –13.34, –4.52) (Table
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ). Ikilinganishwa na kundi la wastani la ProS, washiriki katika kundi la juu la ProS walifikia hatari sawa ya CRC ya ~4.7 miaka (RAP: 4.67, 95% CI: 1.08, 8.27) mapema, wakati miaka 4.4 (RAP: –4.42, 95% CI: –8.17, –0.66) baadaye kwa washiriki katika kundi la chini la ProS. Wakati wa kulinganisha na kundi la wastani la ComS, washiriki katika kundi la juu la ComS walifikia hatari sawa ya CRC miaka 27.5 (RAP: 27.52, 95% CI: 16.66, 38.37) mapema, wakati miaka ~15.2 (RAP: –15.15, 95% CI: –23.78, –6.52) baadaye kwa washiriki katika kundi la chini la ComS. Makadirio ya RAP na 95% CI katika vikundi tofauti vya hatari katika makundi ya mafunzo na uthibitishaji yanapatikana katika Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      6
     </xref>
     <sup/>
     . Wakati uchanganuzi ulipunguzwa kwa washiriki bila historia ya familia ya CRC na bila uchunguzi, matokeo kama hayo yalionekana (Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      7
     </xref>
     ).
     <table-wrap id="Tab2">
      <label>
       Table 2
      </label>
      <caption xml:lang="en">
       <p>
        Muda wa maendeleo ya hatari (RAP) na umri wa kuanza kuangalia saratani ya coloni (CRC) kwa washiriki katika hatari tofauti
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th>
          <p>
           Alama ya hatari
          </p>
         </th>
         <th>
          <p>
           Kesi
          </p>
         </th>
         <th>
          <p>
           Simulizi
          </p>
         </th>
         <th>
          <p>
           RAP (95% CI) (miaka)
          </p>
         </th>
         <th>
          <p>
           Umri wa kuanza kuangalia saratani ya coloni (CRC) (miaka)
          </p>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="5">
          <p>
           PRS
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Chini
          </p>
         </td>
         <td>
          <p>
           183
          </p>
         </td>
         <td>
          <p>
           25,932
          </p>
         </td>
         <td>
          <p>
           –8.93 (–13.34, –4.52)
          </p>
         </td>
         <td>
          <p>
           &gt;60
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Wastani
          </p>
         </td>
         <td>
          <p>
           149
          </p>
         </td>
         <td>
          <p>
           12,909
          </p>
         </td>
         <td>
          <p>
           ref
          </p>
         </td>
         <td>
          <p>
           53
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Juu
          </p>
         </td>
         <td>
          <p>
           399
          </p>
         </td>
         <td>
          <p>
           12,659
          </p>
         </td>
         <td>
          <p>
           17.87 (12.91, 22.83)
          </p>
         </td>
         <td>
          <p>
           41
          </p>
         </td>
        </tr>
        <tr>
         <td colspan="5">
          <p>
           ProS
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Chini
          </p>
         </td>
         <td>
          <p>
           210
          </p>
         </td>
         <td>
          <p>
           25,905
          </p>
         </td>
         <td>
          <p>
           –4.42 (–8.17, –0.66)
          </p>
         </td>
         <td>
          <p>
           57
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Wastani
          </p>
         </td>
         <td>
          <p>
           196
          </p>
         </td>
         <td>
          <p>
           12,862
          </p>
         </td>
         <td>
          <p>
           ref
          </p>
         </td>
         <td>
          <p>
           47
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Juu
          </p>
         </td>
         <td>
          <p>
           325
          </p>
         </td>
         <td>
          <p>
           12,733
          </p>
         </td>
         <td>
          <p>
           4.67 (1.08, 8.27)
          </p>
         </td>
         <td>
          <p>
           46
          </p>
         </td>
        </tr>
        <tr>
         <td colspan="5">
          <p>
           ComS
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Chini
          </p>
         </td>
         <td>
          <p>
           140
          </p>
         </td>
         <td>
          <p>
           25,976
          </p>
         </td>
         <td>
          <p>
           –15.15 (–23.78, –6.52)
          </p>
         </td>
         <td>
          <p>
           &gt;60
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Wastani
          </p>
         </td>
         <td>
          <p>
           140
          </p>
         </td>
         <td>
          <p>
           12,917
          </p>
         </td>
         <td>
          <p>
           ref
          </p>
         </td>
         <td>
          <p>
           48
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Juu
          </p>
         </td>
         <td>
          <p>
           451
          </p>
         </td>
         <td>
          <p>
           12,607
          </p>
         </td>
         <td>
          <p>
           27.52 (16.66, 38.37)
          </p>
         </td>
         <td>
          <p>
           &lt;40
          </p>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        <italic>
         RAP
        </italic>
        muda wa maendeleo ya hatari,
        <italic>
         CI
        </italic>
        uaminifu wa 95%,
        <italic>
         PRS
        </italic>
        alama ya hatari ya kijeni,
        <italic>
         ProS
        </italic>
        alama ya hatari ya protini,
        <italic>
         ComS
        </italic>
        alama ya hatari iliyojumuishwa.
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
   </sec>
   <sec id="Sec9">
    <title>
     Umri wa Kuanza Kuangalia CRC uliobinafsishwa na Hatari
    </title>
    <p id="Par13">
     Hatari ya jumla ya miaka 10 ya kukutana na CRC ilihesabiwa kwa ajili ya kuamua umri wa kuanza kusoma kwa watu binafsi kwa vikundi tofauti vya hatari. Umri wa washiriki walio na hatari ya chini, ya kati, au ya juu ya PRS waliofikia hatari ya jumla ya miaka 10 ya CRC sawa na hatari ya wastani kwa umri wa miaka 50 katika idadi ya watu walio na hatari ya kawaida ilikuwa &gt;60, 53, na 41 miaka (Fig.
     <xref ref-type="fig" rid="Fig4">
      4e
     </xref>
     , Jedwali
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ). Umri wa washiriki walio na hatari ya chini, ya kati, au ya juu ya ProS waliofikia hatari ya jumla ya miaka 10 ya CRC sawa na hatari ya wastani ya idadi ya watu kwa umri wa miaka 50 ilikuwa 57, 47, na 46 miaka (Fig.
     <xref ref-type="fig" rid="Fig4">
      4f
     </xref>
     , Jedwali
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ). Wakati wa kuchanganya ProS, PRS, na QCancer-S, umri wa washiriki walio na hatari ya chini, ya kati, au ya juu ya ComS waliofikia hatari ya jumla ya miaka 10 ya CRC sawa na hatari ya wastani kwa umri wa miaka 50 katika idadi ya watu walio na hatari ya kawaida ilikuwa &gt;60, 48, na &lt;40 miaka (Fig.
     <xref ref-type="fig" rid="Fig4">
      4g
     </xref>
     , Jedwali
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ). Matokeo kama hayo yalionekana pia katika washiriki bila historia ya familia ya CRC na bila kusoma (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      7
     </xref>
     , Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM4">
      7
     </xref>
     ).
    </p>
   </sec>
  </sec>
  <sec id="Sec10" sec-type="discussion">
   <title>
    Jadiliano
   </title>
   <p id="Par14">
    Kwa kutumia mkakati wa hatua mbili, tulibainisha viambajengo vya CRC vinavyotokana na damu na tulipendelea viambatisho 15 vya protini kwa ajili ya utambuzi wa hatari. Muundo wa utabiri unaochanganya viambajengo vya protini na mambo ya kijeni (kwa mfano, PRS) na yasiyo ya kijeni (kwa mfano, QCancer-15) ulifanya kazi vizuri zaidi katika vipimo vyote kuliko QCancer-15 pekee. Zaidi ya hayo, muundo uliojumuishwa uligawanya kwa uwazi hatari ya kuanza kwa CRC na ulipata umri wa kuanza kusoma kwa watu binafsi kwa ajili ya kusoma CRC. Ikilinganishwa na kikundi cha hatari ya wastani, washiriki walio na hatari ya juu ya ProS, PRS, au ComS walifikia hatari sawa ya CRC miaka 4.7, 17.9, au hata 27.5 mapema, wakati 4.4, 8.9 au 15.2 miaka baadaye katika kikundi cha hatari ya chini cha ProS, PRS, au ComS. Wakati wa kurejelea idadi ya watu walio na hatari ya kawaida waliokuwa na umri wa miaka 50, washiriki walio na hatari ya juu ya ProS, PRS, au ComS walipendekezwa kuanza kusoma umri wa miaka 46, 41, au kabla ya miaka 40, wakati vikundi vinavyolingana vya alama za chini vilipendekezwa kuanza kusoma umri wa miaka 57 au baada ya miaka 60. Matokeo kama hayo yalionekana pia katika washiriki bila historia ya familia ya CRC na bila kusoma.
   </p>
   <p id="Par15">
    Muundo wa utafiti wa hatua mbili ulibainisha na kupendelea viambatisho 15 vya protini vinavyohusiana na hatari ya CRC. Wingi wao wamekuwa na ushahidi unaoripotiwa kuwa na uhusiano na hatari ya CRC, utabiri, au majibu kwa matibabu katika kiwango cha protini (kwa mfano, TFF1, LTBP2, PZP), usemi wa mRNA (kwa mfano, TFF1, LTBP2, WFDC2, CDON), methylation ya DNA (kwa mfano, PON3), au polymorphisms za jeni (kwa mfano, CR2)
    <sup>
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ,
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
    </sup>
    . TFF1 (Trefoil factor 1), inaungama kwenye wanachama wa familia ya trefoil, ambayo ni protini zinazotolewa kwa utulivu zinazonyeshwa katika mkojo wa gastrointestinal. Kwa mstari na matokeo yetu, utafiti uliopita uliripoti kuwa kiwango cha TFF1 cha damu kilikuwa cha juu zaidi katika wagonjwa wa CRC kuliko watu walio na afya njema, na kiwango cha mRNA cha TFF1 kilikuwa kilichoongezeka katika tishu za CRC kuliko tishu za kawaida zilizo karibu na tishu za CRC na kukuza tabia ya ugonjwa wa kolonikansi kwa njia ya kuhamishwa kwa epithelial-mesenchymal
    <sup>
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
    </sup>
    . LTBP2 (Latent-transforming growth factor beta-binding protein 2) ni mwanachama wa familia ya fibrillin/LTBP. Kiwango cha mRNA na protini cha LTBP2 katika tishu za CRC kiliripotiwa kuwa cha juu zaidi kuliko katika tishu za kawaida zilizo karibu, na kiwango cha juu cha protini ya LTBP2 kilihusishwa na maisha duni ya jumla katika wagonjwa wa CRC, ikipendekeza kuwa LTBP2 inaweza kutenda kama oncogene katika maendeleo ya CRC na kama kipimo muhimu cha kutabiri utabiri wa CRC
    <sup>
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
    </sup>
    . Pia tulionyesha athari ya kulinda ya protini ya PZP (Pregnancy zone protein) kwa hatari ya kuanza kwa CRC. Vile vile, Wang et al. waliripoti kuwa kiwango cha protini ya PZP cha damu kilihusiana na majibu kwa matibabu ya chemoradiation (nCRT), na wagonjwa wa saratani ya rectum wenye kiwango cha juu cha PZP walitendeka kwa majibu kamili ya patholojia, na thamani ya kutabiri kwa saratani ya rectum na nCRT
    <sup>
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
    </sup>
    .
   </p>
   <p id="Par16">
    Mbinu ya kujiandaa kwa msingi wa utabiri wa hatari ya mtu binafsi imeelezewa kama mustakabali wa utambuzi wa mapema wa magonjwa ya saratani, ikisisitiza tathmini ya hatari ya saratani ya mambo ya kimazingira, vigezo vya kijeni vilivyopitishwa, na vigezo vya omics (hasa vigezo vya protini)
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
    </sup>
    . Utafiti uliopita umetoa miundo ya utabiri wa hatari ya CRC kulingana na PRS pekee au vigezo visivyo vya kijeni au kuchanganya vyote viwili na kugundua kuwa miundo iliyochanganya PRS na vigezo visivyo vya kijeni ilifanya kazi vizuri zaidi kuliko vigezo visivyo vya kijeni pekee au PRS pekee
    <sup>
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
    </sup>
    . Hasa, utafiti wetu uliopita uliotumia SNPs 116 muhimu za GWAS ulitoa C-statistic ya 0.6
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
    </sup>
    . Thomas et al. waliripoti C-statistic ya 0.65 kwa hatari ya CRC kulingana na muundo wa PRS pekee wa cross-ancestry katika watu wasio Wahispania
    <sup>
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
    </sup>
    . Briggs et al. walichanganya QCancer na PRS kutoa C-statistic ya 0.73 katika kutabiri hatari ya CRC kwa wanaume na 0.69 kwa wanawake, na utafiti mwingine uliripoti C-statistic ya 0.72 baada ya kuchanganya PRS na vigezo visivyo vya kijeni
    <sup>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
    </sup>
    . Zaidi ya hayo, utafiti wa kesi-kontrol katika idadi ya watu ya Marekani ulionyesha uboreshaji wa utambuzi baada ya kuongeza vigezo 11 vya protini vya damu vilivyotajwa na utafiti uliopita kulingana na mkakati wa mteja katika muundo wa vigezo visivyo vya kijeni, na C-statistic ya 0.66–0.73
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Kwa ufanisi, kazi yetu ilisaidia na kuendeleza matokeo haya. Hata kama kulikuwa na tofauti katika ufunikaji wa protini (mkakati wa mteja dhidi ya proteome), muundo wa utafiti, na idadi ya watu, protini (IGFBP3) iliyotumika katika muundo wao na protini (IGFBP4) iliyotumika katika muundo wetu zote zinaungama kwenye familia ya protini ya insulin-like growth factor-binding, ambayo inaonyesha uwezekano wa kufanana katika kiwango fulani. Kwa kuchanganya viambajengo vya protini na PRS na QCancer-15, tulitoa muundo uliojumuishwa na C-statistic ya 0.79 kwa ajili ya kutabiri hatari ya kukutana na CRC katika kundi la watu, ambalo lilionyesha utendakazi bora zaidi kuliko miundo ya QCancer-15 au PRS pekee katika makundi ya mafunzo na uthibitishaji. Zaidi ya hayo, matokeo kutoka kwa uchanganuzi wa mstari wa uamuzi na makunyanzi ya Kaplan–Meier yalionyesha faida kubwa ya muundo uliojumuishwa ikilinganishwa na muundo wa QCancer-15 pekee na ilipendekeza matumizi ya kimatibabu yanayowezekana katika utambuzi wa hatari ya CRC.
   </p>
   <p id="Par17">
    Umri wa kuanza kusoma unaolingana na hatari una umuhimu mkubwa wa kimatibabu na afya ya umma kwa ajili ya kuzuia magonjwa ya saratani kwa mtu binafsi. Utafiti uliopita uliotegemea historia ya familia ya CRC ulibaini kuwa washiriki walio na historia tofauti za familia walifikia hatari ya jumla ya miaka 10 ya CRC sawa na hatari kwa umri wa miaka 50 katika idadi ya watu walio na hatari ya kawaida miaka 3–29 mapema
    <sup>
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Utafiti mwingine uliozingatia jinsia na PRS kwa kutumia mbinu ya RAP ulibaini kuwa watu walio na PRS ya chini au ya juu zaidi walifikia hatari sawa ya kuanza kwa CRC miaka 8–10 baadaye au mapema kuliko watu walio na PRS ya kati, na wanaume walio na PRS ya juu zaidi walifikia hatari inayolingana miaka 16 mapema kuliko wanawake walio na PRS ya kati
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
    </sup>
    . Kwa ufanisi, utafiti wetu uliotumia mbinu za RAP na hatari halisi (kwa mfano, hatari ya jumla ya miaka 10) na kupata makadirio sawa kwa umri wa kuanza kusoma unaolingana na hatari ya CRC. Tulipata kuwa washiriki walio na PRS ya juu walifikia hatari sawa ya CRC miaka 17.9 mapema kuliko washiriki walio na PRS ya kati, wakati washiriki walio na PRS ya chini walikuwa miaka 8.9 baadaye kuliko kikundi cha kati. Vile vile, wakati wa kutumia idadi ya watu walio na hatari ya kawaida waliokuwa na umri wa miaka 50, umri wa washiriki walio na PRS ya juu au ya chini uliofikia hatari ya jumla ya miaka 10 ya CRC sawa na hatari inayolingana ilikuwa miaka 41 au &gt;60. Zaidi ya hayo, tuliongeza mbinu hizi kwa proteomics na kutabiri umri wa kuanza kusoma CRC kwa washiriki walio na ProS ya juu au ya chini kuwa miaka 46 au 57. Wakati wa kuchanganya QCancer-15, PRS, na ProS, umri uliofikia hatari sawa katika vikundi tofauti vya hatari ulionyesha mgawanyiko mkubwa zaidi. Washiriki walio na ComS ya juu walifikia hatari sawa ya CRC miaka 27.5 mapema kuliko washiriki walio na kikundi cha kati, wakati washiriki walio na ComS ya chini walikuwa miaka 15.2 baadaye kuliko kikundi cha kati. Umri wa kuanza kusoma unaolingana na hatari ya CRC kwa washiriki walio na hatari ya juu au ya chini ulikadiriwa kuwa kabla ya miaka 40 au baada ya miaka 60. Matokeo kama hayo yalionekana pia katika washiriki bila historia ya familia ya CRC na bila kusoma ambao kwa kawaida wana hatari ya chini na wanaonekana kirahisi. Kwa ujumla, matokeo haya yalisaidia ushahidi thabiti kwa ajili ya kukuza proteomics katika mazoezi ya kimatibabu, ambayo inaweza kuchangia kuboresha tathmini ya hatari ya mtu binafsi na kusoma CRC na ukuzaji wa dawa za kina kwa ajili ya CRC
    <sup>
     <xref ref-type="bibr" rid="CR27">
      27
     </xref>
    </sup>
    .
   </p>
   <p id="Par18">
    Wazo hili lina nguvu fulani. Kwanza, muundo wa hatua mbili uliotokana na teknolojia za proteomiki za juu za kasi zilitumika kutambua mifumo ya proteomiki inayohusiana na CRC, ambayo ilihakikisha kuwa protini zilizo na uhusiano thabiti na CRC katika idadi tofauti za watu na majukwaa ya proteomiki zilitumika kwa uundaji wa muundo, na kuboresha ujumuishaji wa matokeo haya. Pili, kikundi cha kijamii kilichotokana na idadi kubwa ya watu, uwakilishi mzuri, na kufuatilia muda mrefu kuliruhusu kujenga muundo wa utabiri wa CRC kwa watu wa kawaida. Tatu, kuchanganya mifumo ya proteomiki inayotokana na damu na mambo ya kijeni na yasiyo ya kijeni iliyothibitishwa vyema ilitoa msomobo wa hali ya afya ya binadamu, ambayo ilichangia utambuzi wa hatari zaidi na wa kina kwa CRC ili kusaidia kuzingatia rasilimali zilizokithiri kwa watu walio na hatari kubwa. Nne, RAP na hatari ya kujumlisha kwa miaka 10 zilitoa matokeo sawa kwa ajili ya kushauri kuhusu umri wa kuanza kusoma hatari za CRC, ambayo ina maana ya uthabiti na uaminifu wa matokeo ya sasa. Zaidi ya hayo, viambajengo vinavyohitajika kwa ajili ya ujenzi wa muundo vinaweza kupatikana kutoka kwa taarifa za kibinafsi na kipimo kimoja cha damu ambacho si cha uvamizi (kwa mfano, damu), ambacho kilihakikisha urahisi na kukubalika. Hata hivyo, vikwazo vingi vya utafiti huu vinahitaji kuzingatiwa kwa makini. Kwanza, ingawa vigezo vya proteomiki vya CRC viligunduliwa kwa muundo wa hatua mbili uliotokana na idadi ya watu wa China na UKBB, muundo wa utabiri ulianzishwa katika UKBB (ikiwa ni pamoja na watu wa asili ya Ulaya na wasio wa Ulaya) na uthibitishaji wa ndani pekee. Utafiti zaidi uliozingatia idadi ya watu za nje ilihitajika ili kutathmini ujumuishaji kabla ya kutumia matokeo ya sasa katika huduma za kawaida. Pili, RAP na hatari ya kujumlisha kwa miaka 10 haiwezi kutumika katika kutathmini umri wa kuanza kusoma hatari za CRC katika makundi tofauti ya QCancer-S kwa sababu ya taarifa za umri zenyewe zilizojumuishwa na kudhibitiwa katika QCancer-S. Utafiti zaidi wa kutathmini ushiriki wa mambo yasiyo ya kijeni yaliyothibitishwa vyema (iskipaji ya umri) katika umri wa kuanza kusoma hatari za CRC unaweza kuwa wa kusisimua. Zaidi ya hayo, ingawa makadirio mengi ya RAPs yalikuwa sawa kati ya kundi la mafunzo na kundi la uthibitishaji, makadirio ya RAP kwa vikundi vingine vya alama za hatari hayakuwa na maana katika kundi la uthibitishaji, ambayo inaweza kuhusishwa na idadi ndogo ya kesi. Hatimaye, si tu umri wa kuanza kusoma lakini pia muda wa kusoma unajumuisha mikakati ya kusoma. Muda wa kusoma kwa ajili ya kusoma hatari za CRC unahitaji kuchunguzwa na masomo ya siku zijazo.
   </p>
   <p id="Par19">
    Kwa hitimisho, ujumuishaji wa proteomiki ya damu na PRS na QCancer-15 ulionyesha utendakazi bora kwa ajili ya utambuzi wa hatari na athari za kimatibabu kwa ajili ya kubainisha umri wa kuanza kusoma hatari za CRC. Hii inaweza kuchangia katika mchakato wa kufanya maamuzi kwa ajili ya kusoma hatari za CRC, na uwezo wa kupunguza mzigo wa kusoma kwa watu walio na hatari ndogo, wakati wa kuboresha viwango vya kusoma. Utafiti zaidi wa kutathmini kukubalika, urahisi, na gharama ya muundo uliojumuishwa na umri wa kuanza kusoma hatari unahitajika.
   </p>
  </sec>
  <sec id="Sec11" sec-type="methods">
   <title>
    Mbinu
   </title>
   <sec id="Sec12">
    <title>
     Idhini ya Maadili na Kuhusika
    </title>
    <p id="Par20">
     Idhini ya kimaadili kwa ajili ya hatua ya ugunduzi ya utafiti huu ilipatikana kutoka kwa Kamati za Maadili za Hospitali ya Pili ya Chuo Kikuu cha Zhejiang (2023-1190). UKBB iliidhinishwa na Kamati ya Maadili ya Kitaifa ya Kaskazini Magharibi (11/NW/0382). Washiriki wote walitoa kibali cha kuandikwa, na utafiti huu ulifanywa kwa mujibu wa Azimio la Helsinki.
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     Muundo wa Utafiti na Washiriki
    </title>
    <p id="Par21">
     Mchoro wa mtiririko unaonyesha muundo wa jumla wa utafiti (Fig.
     <xref ref-type="fig" rid="Fig1">
      1
     </xref>
     ). Kwa ufupi, kwa kutumia mkakati wa hatua mbili, kwanza tulichunguza vigezo vya protini vya CRC kwa uchambuzi wa tofauti wa proteomiki ulioenea kwa msingi wa muundo wa kesi-kudhibiti na kuithibitisha katika kikundi cha kijamii kilichotokana na idadi kubwa ya watu. Kisha, ProS, QCancer-S, na PRSs zilijengwa na kuunganishwa ili kubuni muundo wa utabiri wa hatari ya CRC kwa msingi wa kikundi cha kijamii kilichotokana na idadi kubwa ya watu. Hatimaye, muundo uliojumuishwa ulithibitishwa katika utendakazi wa utabiri na manufaa ya kimatibabu yanayowezekana (kwa mfano, manufaa ya net, utambuzi wa hatari, na umri wa kuanza kusoma hatari za awali za CRC).
    </p>
    <p id="Par22">
     Hatua ya ugunduzi ilijumuisha kesi 150 mpya za CRC (masafa ya umri: 44–89 miaka) na watu 50 walioambatishwa kwa umri na jinsia kutoka Hospitali ya Pili ya Chuo Kikuu cha Zhejiang. Kikundi cha uthibitishaji kilijumuisha kesi za CRC na watu wasio na CRC kutoka UKBB, waliochaguliwa kati ya 2006 na 2010. Washiriki wenye vipimo vya proteomiki walichaguliwa. Baada ya kuwatenga watu walio na CRC wakati wa kuajiriwa na data ya kijeni iliyokosekana, jumla ya watu 52,231 (kesi 731 za CRC, watu 51,500 wasio na CRC) wenye umri kati ya miaka 39 na 70 kutoka UKBB walibaki.
    </p>
   </sec>
   <sec id="Sec14">
    <title>
     Ufafanuzi wa Matokeo
    </title>
    <p id="Par23">
     Matokeo ya msingi yalikuwa uchunguzi wa CRC, ambao uliwekwa kama neoplazamu za kutisha za coloni na rectum, zilizotambuliwa na mtaalamu wa magonjwa na pathologist katika kundi la utafiti, au kwa kutumia Utambulisho wa Kimataifa wa Magonjwa (ICD, ICD-9: 153, 154.0, 154.1; au ICD-10: C18-C20) katika UKBB kupitia uhusiano wa data ya hospitali na saraka za magonjwa na vifo. Tarehe ya kujiandikisha kwa mchukuaji katika UKBB ilichukuliwa kama mwanzo wa kipindi cha kufuatilia, na kufuatilia kilikatishwa kwenye tarehe ya uchunguzi wa CRC, kifo, hasara ya kufuatilia, au mwisho wa kipindi cha kufuatilia kilichopatikana (Machi 31, 2021), kila moja ikija kwanza.
    </p>
   </sec>
   <sec id="Sec15">
    <title>
     Viwango vya Proteomics vya Damu
    </title>
    <p id="Par24">
     Machupo ya damu yalichukuliwa kutoka kwa washiriki wakati wa kujiandikisha, na sampuli za plasma zilichakatwa na kuhifadhiwa kwa -80 °C. Kupima protein iliyopatikana kwa kutumia iodo Tandem Mass Tags (TMT)-6plex quantitative proteomics katika kundi la utafiti. Segments za peptide zilikuwa za kiasi kwa uwiano wa njia za sampuli za CRC kwa njia za kundi la udhibiti na zilipokea Log
     <sub>
      2
     </sub>
     ubadilishaji na kurekebishwa kwa kutumia mbinu ya quantiles. Maelezo kuhusu kupima proteomic, uchakataji, na udhibiti wa ubora (QC) yanatolewa katika Mbinu za Ziada. Baada ya QC, jumla ya protini 606 zilipeanwa na kujumuishwa katika uchambuzi unaofuata (Data za Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      8
     </xref>
     ).
    </p>
    <p id="Par25">
     Katika UKBB, maelezo kuhusu uteuzi wa sampuli, kupima proteomic, uchakataji, na QC yametajwa mahali pengine
     <sup>
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     . Kwa ufupi, wingi wa protini 2923 ulipimwa kwa kutumia Olink Proximity Extension Assay, na vipimo vilivyotolewa kama maadili ya usemi wa protini iliyobadilishwa kwa Log
     <sub>
      2
     </sub>
     . Maadili ya protini yaliyo chini ya kiwango cha kugundua (LOD) yalibadilishwa kwa kugawanya LOD kwa mzizi wa mraba wa 2. Vipimo vya protini vilivyokosekana vilijazwa kwa maadili ya wastani. Kwa protini zilizo na usemi tofauti kati ya visa vya CRC na udhibiti katika hatua ya utafiti, tulithibitisha zaidi uhusiano wao na hatari ya CRC kulingana na muundo wa kundi la utafiti katika UKBB.
    </p>
   </sec>
   <sec id="Sec16">
    <title>
     Uchambuzi wa Takwimu
    </title>
    <sec id="Sec17">
     <title>
      Ufafanuzi wa Sifa za Msingi
     </title>
     <p id="Par26">
      Jaribio la Kolmogorov–Smirnov la utawala lililotumika kutambua aina za usambazaji wa vigeu vya mfululizo. Wastani (IQR) ulitumika kuwaelezea vigeu vya mfululizo, na idadi (asilimia) iliyotumika kuwaelezea vigeu vya aina mbalimbali.
     </p>
    </sec>
   </sec>
   <sec id="Sec18">
    <title>
     Kutambua Viashiria vya Protein vya CRC
    </title>
    <p id="Par27">
     Mbinu ya hatua mbili ilichukuliwa kutambua ishara za proteomic zinazohusiana na CRC. Katika hatua ya utafiti iliyotegemea muundo wa kesi na udhibiti, uchanganuzi wa mambo ya msingi na matrix ya mgawo wa kuhusiana wa Pearson zilitumika kutambua sampuli za nje (Mbinu za Ziada), na sampuli 20 zenye utofauti wa kiasi zilitambuliwa (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      8
     </xref>
     ). Baada ya kuondoa sampuli za nje, uchanganuzi wa tofauti wa usemi wa protini ulioenea kwa kutumia pakiti ya ‘limma’ ulifanywa kutambua protini zilizoongezeka (Log
     <sub>
      2
     </sub>
     FC &gt; 0) au kupungua (Log
     <sub>
      2
     </sub>
     FC
    </p>
   </sec>
   <sec id="Sec19">
    <title>
     Ufafanuzi wa QCancer-15
    </title>
    <p id="Par28">
     Wabashiri wa QCancer-15 walikuwa wameandikwa kulingana na sifa za msingi katika UKBB zilizoambatana kwa karibu iwezekanavyo na muundo asilia
     <sup>
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
     </sup>
     . Wabashiri wa QCancer-15 walijumuisha umri (umri wakati wa kuajiriwa), jinsia, kiwango cha Townsend cha kudhoofisha, eneo la kijiografia, viwango vya msingi vya mwili (BMI), hali ya kuvuta sigara, kuchukua pombe, historia ya familia ya CRC, na historia ya matibabu yaliyopita. Watu binafsi walio na data iliyokosekana katika vigezo hivi walikuwa wamepangwa katika kundi la “Kukosekana” kwa kila kipengele kinachofaa. Maelezo katika uandishi wa wabashiri hawa yanapatikana katika Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      9
     </xref>
     <sup/>
     . Kwa ajili ya ujumuishaji katika idadi nyingine ya watu, tuliondoa kigezo cha eneo la kijiografia ambacho kilikuwa kimeundwa mahsusi kwa idadi ya watu wa Uingereza kutoka kwa wabashiri wa QCancer-15.
    </p>
   </sec>
   <sec id="Sec20">
    <title>
     Mbinu za Kupata Alama ya Hatari ya Jenetiki (PRS)
    </title>
    <p id="Par29">
     Meta-GWASs za CRC za urithi wa Ulaya (matukio 21,731 na udhibiti 47,444 wa urithi wa Asia Mashariki; matukio 78,473 na udhibiti 107,143 wa urithi wa Ulaya) hadi sasa zilitumika kutoa saizi ya athari ya kila kipengele cha urithi cha kibinafsi (SNP). LDpred2 ilitumika kuunda PRS ya jumla ya jeni, ambayo inategemea mbinu ya Bayesian na inahesabu usambazaji wa urithi (LD) kati ya SNPs
     <sup>
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
     </sup>
     . Mifano miwili tofauti ya LDpred2 ilifanywa, ikijumuisha muundo wa auto (LDpred2-auto) na muundo wa gridi (LDpred2-grid), kwa kutumia seti ya data ya HapMap3+ kama marejeleo. Jumla ya PRS 2 zilitengenezwa. Maelezo yanapatikana katika Mbinu za Ziada.
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     Ujenzi wa Alama za Hatari na Maendeleo ya Muundo wa Kubashiri
    </title>
    <p id="Par30">
     Saini za protini zinazohusiana na CRC zilichaguliwa zaidi kwa kutumia LASSO-Cox regression kati ya protini ambazo zilipitia jaribio la hatua mbili, na jumla ya protini 15 ziliachwa. ProS au QCancer-S iliyopimwa (risk Score=h0(t)*exp(β1×1 + β2×2 + …+βnXn)) ilijengwa kulingana na protini 15 zilizochaguliwa au wabashiri wa QCancer-15 katika UKBB kwa kutumia kazi ya ‘predict’ ya R package ‘caret’ (toleo 6.0.94), mtawalia. Ambapo Xn ilikuwa kiwango cha protini (au kibashiri cha QCancer-15) na βn ilikuwa mgawo wa protini (au kibashiri cha QCancer-15) unaohusiana na hatari ya CRC iliyopatikana kutoka kwa muundo wa CPH, na h0(t) ilikuwa hatari ya msingi. Maelezo yanapatikana katika Mbinu za Ziada. Kisha, washiriki wa UKBB waligawanywa kwa nasibu katika vikundi vya mafunzo na uthibitishaji kwa uwiano wa 7:3 kwa kutumia paketi ya ‘caret’. Mifano ya utabiri wa hatari ya CRC iliyoundwa kulingana na QCancer-S, QCancer-S (ikiwa ni pamoja na eneo la kijiografia), PRS 2, au ProS, mtawalia, kwa kutumia muundo wa CPH na uhalizishaji wa mara 5 katika kikundi cha mafunzo. Kisha, QCancer-S, ProS, na PRS yenye utendakazi bora ziliunganishwa kuunda muundo mchanganyiko wa kutabiri hatari ya maambukizi ya CRC. Mifano hii pia ilithibitishwa kwa kutumia mgawanyiko wa jinsia, tovuti za tumor (koloni au rectum), uchunguzi wa saratani ya bowel (ndio au hapana), na historia ya familia ya CRC (ndio au hapana)
     <sup>
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec22">
    <title>
     Tathmini ya Ufanisi wa Muundo na Manufaa ya Kimatibabu yanayowezekana
    </title>
    <p id="Par31">
     Utendakazi wa muundo ulithibitishwa kwa kutumia vipimo mbalimbali, ikijumuisha eneo chini ya mkunjo wa utambulisho wa vipokezi (AUC, inajulikana kama C-statistic), kalibresha ya hatari ya kweli, manufaa ya net, makadirio ya uwiano wa hatari, mgawanyiko wa hatari, kipindi cha maendeleo ya hatari, na hatari ya jumla ya miaka 10 ya maambukizi ya CRC.
    </p>
   </sec>
   <sec id="Sec23">
    <title>
     Ubaguzi na Uwiano wa Muundo
    </title>
    <p id="Par32">
     Ubaguzi wa mifano hii ulithibitishwa kwa kutumia C-statistic (kipindi cha uaminifu cha 95%, CI) na uhalizishaji wa mara 5 katika kikundi cha mafunzo na kisha kuthibitishwa katika kikundi cha uthibitishaji. Tofauti za utendakazi wa mifano tofauti zililinganishwa kwa kutumia mbinu ya bootstrap, na nakala 500 za uhalizishaji uliogawanywa. Mikunjo ya kalibresha ilichorwa kwa kutumia paketi ya ‘riskRegression’ kuonyesha uwiano kati ya viwango vya matukio yaliyotazamwa na hatari zilizotabiriwa kulingana na mifano ya CPH. Nomogramu ya QCancer-S, PRS, na ProS ilijengwa kwa ajili ya kutabiri miaka 5-, 10-, na 15- bila CRC
     <sup>
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec24">
    <title>
     Uchambuzi wa Mstari wa Uamuzi
    </title>
    <p id="Par33">
     Ili kutathmini uwezo wa kimatibabu wa miundo ya utabiri kuhusu utendakazi uliozuiwa kwa CRC (kwa mfano, utambuzi), uchambuzi wa mkunjo wa maamuzi ulifanywa kwa kutumia pakiti ya ‘ggDCA’ kuhesabu manufaa ya mtandao (NB) yaliyopatikana kwa kutumia QCancer-S pekee au muundo uliojumuishwa (QCancer-S + PRS + ProS) kuchagua watu kwa ajili ya utambuzi wa colonoscopy. NB = ((true positives)/
     <italic>
      n
     </italic>
     ) – ((false positives)/
     <italic>
      n
     </italic>
     ) ∗ (
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     /(1−
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     )), ambapo
     <italic>
      n
     </italic>
     ni jumla ya idadi ya watu, na
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     ni kiwango cha hatari (au uwezekano) (kwa mfano, kwa
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     = 1%, inakubalika kufanya colonoscopy kwa washiriki 100 ili kugundua kesi moja ya CRC)
     <sup>
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
     </sup>
     . Tulilinganisha muundo uliojumuishwa na muundo uliozingatia QCancer-S pekee, pamoja na utendakazi kwa hakuna na utendakazi kwa wote. Kupungua kwa idadi ya uwezekano wa uwongo kwa kila watu 100 kilitolewa kwa fomula: 100*(NB ya muundo–NB ya utendakazi wote)/(
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     /(1–
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     )). NBs katika viwango vya hatari vilivyobainishwa zaidi katika muda wa kufuatilia wa wastani (miaka 13.05) ilionekana katika mikunjo ya maamuzi. Thamani za NB kwa viwango vya hatari vilivyobainishwa (1%, 1.5%, 2%, 2.5%, na 3%) ziliorodheshwa.
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     Kadirio la Hazards na Uchambuzi wa Ugawanyaji wa Hatari
    </title>
    <p id="Par34">
     HRs zilichukuliwa kwanza kutoka kwa CPH regression kwa ongezeko la SD katika QCancer-S, PRS, na ProS kwa jumla, ya kijinsia, na hatari mahususi ya CRC. Kisha, QCancer-S, PRS, ProS, na ComS (Mbinu za Ziada) ziligawanywa katika roboduara (Q1- ya chini, Q2, Q3, na Q4- ya juu) kulingana na usambazaji wake katika idadi ya sasa ya UKBB, mtawalia. Kwa sababu ya mwelekeo sawa katika mikunjo ya hatari ya miaka 10, alama za hatari ziliongezwa katika vikundi 3 (wazuri, wastani, na wa juu) (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      9
     </xref>
     ). Hasa, kwa kutumia hatari ya miaka 10 katika idadi ya jumla kama marejeleo, washiriki katika Q3 wenye hatari sawa na idadi ya jumla waligawanywa katika kundi la hatari ya wastani, washiriki katika Q1 na Q2 wenye hatari ya chini kuliko idadi ya jumla waligawanywa katika kundi la hatari ya chini, na washiriki katika Q4 waligawanywa katika kundi la hatari ya juu. HRs (95% CIs) pia zilitolewa kwa vigeu vya aina kwa kutumia kundi la wastani kama marejeleo. Thamani ya utengenezaji wa hatari ya alama za hatari ilitathminiwa kwa mikunjo ya Kaplan–Meier na majaribio ya log-rank.
    </p>
   </sec>
   <sec id="Sec26">
    <title>
     Uchambuzi wa Kipindi cha Kuongezeka kwa Hatari (RAP)
    </title>
    <p id="Par35">
     Ili kubadilisha HRs kwa PRS, ProS, na ComS katika idadi ya miaka ya umri baadaye au mapema kwa watu katika vikundi vya chini au vya juu vya PRS, ProS, na ComS wanaofikia hatari zinazolingana na kundi la marejeleo (yaani, wale katika kiwango cha wastani cha PRS, ProS, au ComS), uchambuzi wa RAP ulifanywa. QCancer-S haikutathminiwa kwa RAP kwa sababu ya taarifa za umri zenyewe zilizojumuishwa na kudhibitiwa katika QCancer-S. Makadirio ya pointi ya RAPs yalitolewa kutoka kwa muundo wa CPH wa aina nyingi, ambao ulijumuisha umri, PRS (ya chini, ya wastani, ya juu), na ProS (ya chini, ya wastani, ya juu), na jinsia na vipengele 10 vya kwanza vya msingi wa kijeni (PCs) kama vigezo, kwa kugawanya mgawo wa regression wa PRS au ProS kwa mgawo wa umri. Wakati wa kuhesabu RAP ya ComS, muundo ulijumuisha umri, ComS (ya chini, ya wastani, ya juu), jinsia, na PCs 10 za kwanza, ambapo RAP ilihesabiwa kwa kugawanya mgawo wa regression wa ComS kwa mgawo wa umri. 95% CIs kwa RAPs zilitolewa kwa kutumia mbinu ya bootstrap, na nakala 500 za bootstrap zilizopangwa.
    </p>
   </sec>
   <sec id="Sec27">
    <title>
     Kukadiria Umri wa Kuanza Kuangalia uliobinafsishwa na Hatari
    </title>
    <p id="Par36">
     Ili kuhesabu zaidi umri wa kuanza kutambua hatari kwa idadi tofauti za vikundi vya hatari, hatari ya miaka 10 ilitolewa. Kwa kuzingatia idadi ya UKBB yote kuwa na habari nyingi na kuwakilisha, tunahesabu umri wa kuanza kutambua hatari kulingana na idadi yote. Hatari ya miaka 10 = 1–exp(–kiwango cha hatari cha miaka 10 cha jumla), ambapo kiwango cha hatari cha miaka 10 cha jumla kilikuwa jumla ya kiwango cha hatari cha kila mwaka cha kila umri
     <sup>
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
     </sup>
     . Kiwango cha hatari cha kila mwaka kilihesabiwa kwa kugawanya idadi ya kesi kwa kila umri kwa miaka ya mtu kwa kila umri. Kwa kuzingatia kwamba umri wa kuanza kutambua hatari ni miaka 50 kwa watu walio na hatari ya wastani kwa mujibu wa miongozo ya sasa, tulihesabu umri wa kuanza kutambua hatari kama umri ambao watu wenye hatari mahususi ya CRC walifikia kiwango sawa cha hatari ya miaka 10 na idadi ya jumla ya umri wa miaka 50
     <sup>
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
     </sup>
     . Majaribio yote ya takwimu yalifanywa upande mmoja na yalifanywa kwa kutumia R version 4.2.2.
    </p>
   </sec>
   <sec id="Sec28">
    <title>
     Ripoti ya Maelezo
    </title>
    <p id="Par37">
     Maelezo zaidi kuhusu muundo wa utafiti yanapatikana katika
     <xref ref-type="supplementary-material" rid="MOESM5">
      Maelezo ya Jumla ya Mfululizo wa Nature
     </xref>
     yanayounganishwa na makala haya.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Shukrani
   </title>
   <p>
    Wananchi wanashukuru washiriki wote kutoka Hospitali ya Pili ya Chuo Kikuu cha Zhejiang University School of Medicine na UK Biobank, taasisi na wafanyakazi wao kwa kutoa data. Q.X. anasaidiwa na National Natural Science Foundation of China (No. 82072360, 82373234) na Mradi wa kituo cha utambuzi na matibabu wa kanda wa Kamati ya Upangaji wa Afya (No. JBZX-201903). X.L. anasaidiwa na Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001), National Nature Science Foundation of China (82204019), na Zhejiang Provincial Clinical Research Center for CANCER (2022E50008, 2024ZY01056). Y.H. anasaidiwa na Zhejiang Province Clinical Research Center for CANCER (2022E50008.2024ZY01056) na Key R&amp;D Program of Zhejiang (2023C03049). Wafadhili hao hawakuwa na jukumu katika muundo wa utafiti, ukusanyaji wa data na uchanganuzi, uamuzi wa kuchapisha, au utayarishaji wa makala.
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Michango ya Waandishi
   </title>
   <p>
    Waandishi hawa ni waandishi wa pamoja: Xue Li, Qian Xiao, Junli Gao. X.L., Q.X., J.-L.G., na J.S. walichangia katika muundo wa utafiti na mpango. Utayarishaji wa nyenzo, ukusanyaji wa data, mbinu, uchanganuzi wa fomu, na utazamaji vilifanywa na J.S., Y.L., J.Z., B.L., na S.Z. H.G., J.-S.G., W.L., J.W., Y.-T.H., na X.K. walichangia katika usimamizi wa mradi. Muswada wa kwanza wa makala uliandikwa na J.S., X.L., Q.X., J-L.G. na waandishi wote waliotangulia walihakikisha na kutoa maoni kuhusu nasaha za awali za makala. X.L. ndiye mtu wa kuwajibika wa utafiti na anahakikisha kuwa waandishi wote waliotajwa wanakidhi vigezo vya uandishi na kwamba hakuna wengine wanaokidhi vigezo ambao wameachwa. Waandishi wote waliosoma na kuidhinisha makala ya mwisho.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Uchunguzi wa Wataalamu
   </title>
   <sec id="FPar1">
    <title>
     Maelezo ya Uchunguzi wa Wataalamu
    </title>
    <p id="Par38">
     <italic>
      Nature Communications
     </italic>
     thanks Jun Zhong and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa Data
   </title>
   <p>
    The raw data of plasma proteomics generated in this study have been deposited in the iProX database under accession code IPX0008947000 (the equivalent ProteomeXChange PXD code: PXD054569) and
    <ext-link ext-link-type="uri" xlink:href="https://www.iprox.cn//page/subproject.html?id=IPX0008947001">
     IPX0008947001
    </ext-link>
    . The UK Biobank data are available under restricted access for data protocol, access can be obtained by registering and applying at
    <ext-link ext-link-type="uri" xlink:href="http://ukbiobank.ac.uk/register-apply/">
     http://ukbiobank.ac.uk/register-apply/
    </ext-link>
    . This study used the UK Biobank data under application number 66354. The result data generated in this study are provided in the Supplementary Information/Source Data file. The CRC GWAS summary statistics
    <sup>
     <xref ref-type="bibr" rid="CR30">
      30
     </xref>
    </sup>
    are available through the GWAS catalog (accession no. GCST90129505).
    <xref ref-type="sec" rid="Sec30">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa Msimbo
   </title>
   <p>
    Analysis code is available at
    <ext-link ext-link-type="uri" xlink:href="https://github.com/shuaidexue/Proteomics-predicted-colorectal-cancer-risk">
     https://github.com/shuaidexue/Proteomics-predicted-colorectal-cancer-risk
    </ext-link>
    .
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Maslahi yanayoshindana
    </title>
    <p id="Par39">
     The authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Marudio
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sung
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
      </article-title>
      <source>
       CA Cancer J. Clin.
      </source>
      <year>
       2021
      </year>
      <volume>
       71
      </volume>
      <fpage>
       209
      </fpage>
      <lpage>
       249
      </lpage>
      <pub-id pub-id-type="doi">
       10.3322/caac.21660
      </pub-id>
      <pub-id pub-id-type="pmid">
       33538338
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sinicrope
        </surname>
        <given-names>
         FA
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Increasing incidence of early-onset colorectal cancer
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       386
      </volume>
      <fpage>
       1547
      </fpage>
      <lpage>
       1558
      </lpage>
      <pub-id pub-id-type="doi">
       10.1056/NEJMra2200869
      </pub-id>
      <pub-id pub-id-type="pmid">
       35443109
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFGrsLnM
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Anderson
        </surname>
        <given-names>
         NL
        </given-names>
       </name>
       <name>
        <surname>
         Anderson
        </surname>
        <given-names>
         NG
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The human plasma proteome: history, character, and diagnostic prospects
      </article-title>
      <source>
       Mol. Cell Proteom.
      </source>
      <year>
       2002
      </year>
      <volume>
       1
      </volume>
      <fpage>
       845
      </fpage>
      <lpage>
       867
      </lpage>
      <pub-id pub-id-type="doi">
       10.1074/mcp.R200007-MCP200
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3sXht1Ciug%3D%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Suhre
        </surname>
        <given-names>
         K
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         MI
        </given-names>
       </name>
       <name>
        <surname>
         Schwenk
        </surname>
        <given-names>
         JM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Genetics meets proteomics: perspectives for large population-based studies
      </article-title>
      <source>
       Nat. Rev. Genet.
      </source>
      <year>
       2021
      </year>
      <volume>
       22
      </volume>
      <fpage>
       19
      </fpage>
      <lpage>
       37
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41576-020-0268-2
      </pub-id>
      <pub-id pub-id-type="pmid">
       32860016
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhslSltLnL
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome
      </article-title>
      <source>
       Genome Med.
      </source>
      <year>
       2023
      </year>
      <volume>
       15
      </volume>
      <pub-id pub-id-type="doi">
       10.1186/s13073-023-01229-9
      </pub-id>
      <pub-id pub-id-type="pmid">
       37726845
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10508028
      </pub-id>
      <elocation-id>
       75
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Prospective
      </article-title>
      <source>
       Cancers
      </source>
      <year>
       2022
      </year>
      <volume>
       14
      </volume>
      <fpage>
       3261
      </fpage>
      <pub-id pub-id-type="doi">
       10.3390/cancers14133261
      </pub-id>
      <pub-id pub-id-type="pmid">
       35805033
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9265260
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhvVCltrrP
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ahn
        </surname>
        <given-names>
         SB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel
      </article-title>
      <source>
       Clin. Proteom.
      </source>
      <year>
       2019
      </year>
      <volume>
       16
      </volume>
      <fpage>
       34
      </fpage>
      <pub-id pub-id-type="doi">
       10.1186/s12014-019-9255-z
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Harlid
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer risk
      </article-title>
      <source>
       Sci. Rep.
      </source>
      <year>
       2021
      </year>
      <volume>
       11
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021NatSR..11.5151H
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41598-021-83968-6
      </pub-id>
      <pub-id pub-id-type="pmid">
       33664295
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7933352
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXlvF2htbw%3D
      </pub-id>
      <elocation-id>
       5151
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fang
        </surname>
        <given-names>
         Z
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Risk prediction models for colorectal cancer: evaluating the discrimination due to added biomarkers
      </article-title>
      <source>
       Int. J. Cancer
      </source>
      <year>
       2021
      </year>
      <volume>
       149
      </volume>
      <fpage>
       1021
      </fpage>
      <lpage>
       1030
      </lpage>
      <pub-id pub-id-type="doi">
       10.1002/ijc.33621
      </pub-id>
      <pub-id pub-id-type="pmid">
       33948940
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhtFGksL7E
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Usher-Smith
        </surname>
        <given-names>
         JA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       External validation of risk prediction models for incident colorectal cancer using UK Biobank
      </article-title>
      <source>
       Br. J. Cancer
      </source>
      <year>
       2018
      </year>
      <volume>
       118
      </volume>
      <fpage>
       750
      </fpage>
      <lpage>
       759
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/bjc.2017.463
      </pub-id>
      <pub-id pub-id-type="pmid">
       29381683
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5846069
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC1MvlsVOhsQ%3D%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hippisley-Cox
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Coupland
        </surname>
        <given-names>
         C
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study
      </article-title>
      <source>
       BMJ Open
      </source>
      <year>
       2015
      </year>
      <volume>
       5
      </volume>
      <fpage>
       e007825
      </fpage>
      <pub-id pub-id-type="doi">
       10.1136/bmjopen-2015-007825
      </pub-id>
      <pub-id pub-id-type="pmid">
       25783428
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4368998
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Briggs
        </surname>
        <given-names>
         SEW
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study
      </article-title>
      <source>
       BMJ
      </source>
      <year>
       2022
      </year>
      <volume>
       379
      </volume>
      <fpage>
       e071707
      </fpage>
      <pub-id pub-id-type="doi">
       10.1136/bmj-2022-071707
      </pub-id>
      <pub-id pub-id-type="pmid">
       36351667
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9644277
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Vocka
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer
      </article-title>
      <source>
       Neoplasma
      </source>
      <year>
       2015
      </year>
      <volume>
       62
      </volume>
      <fpage>
       470
      </fpage>
      <lpage>
       477
      </lpage>
      <pub-id pub-id-type="doi">
       10.4149/neo_2015_056
      </pub-id>
      <pub-id pub-id-type="pmid">
       25866228
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC28Xlt12hsbs%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Huang
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High expression of LTBP2 contributes to poor prognosis in colorectal cancer patients and correlates with the mesenchymal colorectal cancer subtype
      </article-title>
      <source>
       Dis. Mark.
      </source>
      <year>
       2019
      </year>
      <volume>
       2019
      </volume>
      <elocation-id>
       5231269
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy
      </article-title>
      <source>
       BMC Cancer
      </source>
      <year>
       2022
      </year>
      <volume>
       22
      </volume>
      <pub-id pub-id-type="doi">
       10.1186/s12885-022-09960-z
      </pub-id>
      <pub-id pub-id-type="pmid">
       35945555
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9361520
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xit1Cls7zI
      </pub-id>
      <elocation-id>
       868
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Yusufu
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process
      </article-title>
      <source>
       Int. J. Oncol.
      </source>
      <year>
       2019
      </year>
      <volume>
       55
      </volume>
      <fpage>
       789
      </fpage>
      <lpage>
       804
      </lpage>
      <pub-id pub-id-type="pmid">
       31432157
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6741840
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVCgsLs%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Shi
        </surname>
        <given-names>
         LP
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       MicroRNA-149 sensitizes colorectal cancer to radiotherapy by downregulating human epididymis protein 4
      </article-title>
      <source>
       Am. J. Cancer Res
      </source>
      <year>
       2018
      </year>
      <volume>
       8
      </volume>
      <fpage>
       30
      </fpage>
      <lpage>
       38
      </lpage>
      <pub-id pub-id-type="pmid">
       29416918
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5794719
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXntlyitro%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Delloye-Bourgeois
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Sonic Hedgehog promotes tumor cell survival by inhibiting CDON pro-apoptotic activity
      </article-title>
      <source>
       PLoS Biol.
      </source>
      <year>
       2013
      </year>
      <volume>
       11
      </volume>
      <fpage>
       e1001623
      </fpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pbio.1001623
      </pub-id>
      <pub-id pub-id-type="pmid">
       23940460
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3735457
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Baharudin
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Identification of predictive DNA methylation biomarkers for chemotherapy response in colorectal cancer
      </article-title>
      <source>
       Front Pharm.
      </source>
      <year>
       2017
      </year>
      <volume>
       8
      </volume>
      <fpage>
       47
      </fpage>
      <pub-id pub-id-type="doi">
       10.3389/fphar.2017.00047
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zhao
        </surname>
        <given-names>
         Q
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2022NatCo..13.2342Z
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-022-30062-8
      </pub-id>
      <pub-id pub-id-type="pmid">
       35487942
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9055073
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFOhsb%2FE
      </pub-id>
      <elocation-id>
       2342
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fitzgerald
        </surname>
        <given-names>
         RC
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The future of early cancer detection
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       28
      </volume>
      <fpage>
       666
      </fpage>
      <lpage>
       677
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41591-022-01746-x
      </pub-id>
      <pub-id pub-id-type="pmid">
       35440720
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtVGrsLbE
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Thomas
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2023
      </year>
      <volume>
       14
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2023NatCo..14.6147T
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-023-41819-0
      </pub-id>
      <pub-id pub-id-type="pmid">
       37783704
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10545678
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXitVKlsbzE
      </pub-id>
      <elocation-id>
       6147
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Li
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Prediction of colorectal cancer risk based on profiling with common genetic variants
      </article-title>
      <source>
       Int. J. Cancer
      </source>
      <year>
       2020
      </year>
      <volume>
       147
      </volume>
      <fpage>
       3431
      </fpage>
      <lpage>
       3437
      </lpage>
      <pub-id pub-id-type="doi">
       10.1002/ijc.33191
      </pub-id>
      <pub-id pub-id-type="pmid">
       32638365
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVSrsLnM
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kachuri
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2020
      </year>
      <volume>
       11
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2020NatCo..11.6084K
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-020-19600-4
      </pub-id>
      <pub-id pub-id-type="pmid">
       33247094
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7695829
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXisFShtbjO
      </pub-id>
      <elocation-id>
       6084
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tian
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Calculating the starting age for screening in relatives of patients with colorectal cancer based on data from large nationwide data sets
      </article-title>
      <source>
       Gastroenterology
      </source>
      <year>
       2020
      </year>
      <volume>
       159
      </volume>
      <fpage>
       159
      </fpage>
      <lpage>
       168.e3
      </lpage>
      <pub-id pub-id-type="doi">
       10.1053/j.gastro.2020.03.063
      </pub-id>
      <pub-id pub-id-type="pmid">
       32251666
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chen
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Personalized initial screening age for colorectal cancer in individuals at average risk
      </article-title>
      <source>
       JAMA Netw. Open
      </source>
      <year>
       2023
      </year>
      <volume>
       6
      </volume>
      <fpage>
       e2339670
      </fpage>
      <pub-id pub-id-type="doi">
       10.1001/jamanetworkopen.2023.39670
      </pub-id>
      <pub-id pub-id-type="pmid">
       37878311
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10600582
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Qaseem
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians (Version 2)
      </article-title>
      <source>
       Ann. Intern. Med.
      </source>
      <year>
       2023
      </year>
      <volume>
       176
      </volume>
      <fpage>
       1092
      </fpage>
      <lpage>
       1100
      </lpage>
      <pub-id pub-id-type="doi">
       10.7326/M23-0779
      </pub-id>
      <pub-id pub-id-type="pmid">
       37523709
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         BB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Plasma proteomic associations with genetics and health in the UK Biobank
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2023
      </year>
      <volume>
       622
      </volume>
      <fpage>
       329
      </fpage>
      <lpage>
       338
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41586-023-06592-6
      </pub-id>
      <pub-id pub-id-type="pmid">
       37794186
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10567551
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXitVGqsbbJ
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ritchie
        </surname>
        <given-names>
         ME
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       limma powers differential expression analyses for RNA-sequencing and microarray studies
      </article-title>
      <source>
       Nucleic Acids Res.
      </source>
      <year>
       2015
      </year>
      <volume>
       43
      </volume>
      <fpage>
       e47
      </fpage>
      <pub-id pub-id-type="doi">
       10.1093/nar/gkv007
      </pub-id>
      <pub-id pub-id-type="pmid">
       25605792
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4402510
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fernandez-Rozadilla
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
      </article-title>
      <source>
       Nat. Genet.
      </source>
      <year>
       2023
      </year>
      <volume>
       55
      </volume>
      <fpage>
       89
      </fpage>
      <lpage>
       99
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41588-022-01222-9
      </pub-id>
      <pub-id pub-id-type="pmid">
       36539618
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XjtFCktr7L
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Privé
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Arbel
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Vilhjálmsson
        </surname>
        <given-names>
         BJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       LDpred2: better, faster, stronger
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2021
      </year>
      <volume>
       36
      </volume>
      <fpage>
       5424
      </fpage>
      <lpage>
       5431
      </lpage>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btaa1029
      </pub-id>
      <pub-id pub-id-type="pmid">
       33326037
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kuhn
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Building predictive models in R using the caret package
      </article-title>
      <source>
       J. Stat. Softw.
      </source>
      <year>
       2008
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       26
      </lpage>
      <pub-id pub-id-type="doi">
       10.18637/jss.v028.i05
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="other">
      Gerds, T., Ohlendorff, J. &amp; Ozenne, B.
      <italic>
       riskRegression: risk regression models and prediction scores for survival analysis with competing risks
      </italic>
      . R package version 2023.09.08 (2023).
      <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=riskRegression">
       https://CRAN.R-project.org/package=riskRegression
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Vickers
        </surname>
        <given-names>
         AJ
        </given-names>
       </name>
       <name>
        <surname>
         Elkin
        </surname>
        <given-names>
         EB
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Decision curve analysis: a novel method for evaluating prediction models
      </article-title>
      <source>
       Med. Decis. Mak.
      </source>
      <year>
       2006
      </year>
      <volume>
       26
      </volume>
      <fpage>
       565
      </fpage>
      <lpage>
       574
      </lpage>
      <pub-id pub-id-type="doi">
       10.1177/0272989X06295361
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Liese
        </surname>
        <given-names>
         AD
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Assessing the impact of classical risk factors on myocardial infarction by rate advancement periods
      </article-title>
      <source>
       Am. J. Epidemiol.
      </source>
      <year>
       2000
      </year>
      <volume>
       152
      </volume>
      <fpage>
       884
      </fpage>
      <lpage>
       888
      </lpage>
      <pub-id pub-id-type="doi">
       10.1093/aje/152.9.884
      </pub-id>
      <pub-id pub-id-type="pmid">
       11085401
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BD3M%2FkslCrtg%3D%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="other">
      Zheng, Y. et al. Use of breast cancer risk factors to identify risk-adapted starting age of screening in China.
      <italic>
       JAMA Netw. Open
      </italic>
      <bold>
       5
      </bold>
      , e2241441 (2022).
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec29">
     <title>
      Maelezo ya Ziada
     </title>
     <p id="Par40">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM4_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Data 1-9
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM5_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec30">
     <title>
      Data ya Msingi
     </title>
     <p id="Par41">
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM6_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source Data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    Maelezo ya Ziada
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-024-52894-2">
     https://doi.org/10.1038/s41467-024-52894-2
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
